2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN.Post author:alarpharmPost published:13 . 5 . 2022Post category:Media releases You Might Also Like 2022/08/10 ALA-1000 Received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile , Application No. 624-2019 11 . 8 . 2022 2024/02/19 ALA-3000 has received a notice of allowance from Mexican Institute of Industrial Property (IMPI) after examination. (Patent Application No. 2021006029) 29 . 2 . 2024 2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI) 13 . 8 . 2020 2021/11/09 Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients 10 . 11 . 2021 2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021
2022/08/10 ALA-1000 Received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile , Application No. 624-2019 11 . 8 . 2022
2024/02/19 ALA-3000 has received a notice of allowance from Mexican Institute of Industrial Property (IMPI) after examination. (Patent Application No. 2021006029) 29 . 2 . 2024
2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI) 13 . 8 . 2020
2021/11/09 Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients 10 . 11 . 2021
2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021